Amyloidosis: A changing clinical perspective
Date
2007
Authors
Jacobs P.
Ruff P.
Wood L.
Moodley D.
Mansvelt E.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Primary amyloidosis is a plasma cell dyscrasia characterised by excess production of abnormal immunoglobulin light chains with their subsequent accumulation in kidneys, heart, liver as well as gastrointestinal tract and bone marrow 1-21, 2. These tissue deposits take the form of a fibrillar protein which damages the involved organ in proportion to the extent of the infiltration and roughly parallels the duration of the disease. Most cases have evidence of the underlying lymphoplasmacytoid neoplasm recognisable in two ways. Firstly, the monoclone appears in the serum [2]. Secondly is a morphologically and immunohistochemically distinctive cellular infiltrate in the bone marrow [3] that has a specific microscopic and ultrastructural pattern [4-5]. Interestingly occasional patients, who survive long enough, may progress to multiple myeloma [6] but the correlation is variable [7].
Description
Keywords
amyloid protein, cyclophosphamide, doxorubicin, etoposide, immunoglobulin light chain, melphalan, phenylalanine, prednisone, vincristine, adult, aged, amyloidosis, article, blood analysis, cancer combination chemotherapy, cell infiltration, cell ultrastructure, clinical article, correlation analysis, disease duration, female, hematopoietic stem cell transplantation, histopathology, human, human tissue, immunoglobulin production, immunohistochemistry, male, morbidity, mortality, multiple myeloma, priority journal, protein blood level, protein localization, risk assessment, survival, survival time, treatment outcome, treatment response, Adult, Aged, Amyloidosis, Antibodies, Monoclonal, Bone Marrow, Bone Marrow Transplantation, Colchicine, Diagnosis, Differential, Disease Management, Female, Humans, Immunotherapy, Lymphoproliferative Disorders, Male, Melphalan, Methylprednisolone, Middle Aged, Plasma Cells, Prednisone, Radioimmunotherapy, South Africa, Survival Rate
Citation
Hematology
12
2
12
2